Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Offord JR, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med. 2006;354(13):1362–9. https://doi.org/10.1056/NEJMoa054494.

Article  PubMed  CAS  Google Scholar 

Kyle RA, Rajkumar SV. Monoclonal gammopathy of undetermined significance. Br J Haematol. 2006;134(6):573–89. https://doi.org/10.1111/j.1365-2141.2006.06235.x.

Article  PubMed  CAS  Google Scholar 

Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med. 2002;346(8):564–9. https://doi.org/10.1056/NEJMoa01133202.

Article  PubMed  Google Scholar 

Fermand JP, Bridoux F, Dispenzieri A, Jaccard A, Kyle RA, Leung N, et al. Monoclonal gammopathy of clinical significance: a novel concept with therapeutic implications. Blood. 2018;132(14):1478–85. https://doi.org/10.1182/blood-2018-04-839480.

Article  PubMed  CAS  Google Scholar 

Hanewinckel R, van Oijen M, Ikram MA, van Doorn PA. The epidemiology and risk factors of chronic polyneuropathy. Eur J Epidemiol. 2016;31(1):5–20. https://doi.org/10.1007/s10654-015-0094-6.

Article  PubMed  Google Scholar 

Rognvaldsson S, Steingrimsson V, Turesson I, Bjorkholm M, Landgren O, Yngvi KS. Peripheral neuropathy and monoclonal gammopathy of undetermined significance: a population-based study including 15,351 cases and 58,619 matched controls. Haematologica. 2020;105(11):2679–81. https://doi.org/10.3324/haematol.2019.239632.

Article  PubMed  PubMed Central  Google Scholar 

Yeung KB, Thomas PK, King RH, Waddy H, Will RG, Hughes RA, et al. The clinical spectrum of peripheral neuropathies associated with benign monoclonal IgM, IgG and IgA paraproteinaemia. Comparative clinical, immunological and nerve biopsy findings. J Neurol. 1991;238(7):383–91. https://doi.org/10.1007/BF00319857.

Article  PubMed  CAS  Google Scholar 

Steck AJ, Stalder AK, Renaud S. Anti-myelin-associated glycoprotein neuropathy. Curr Opin Neurol. 2006;19(5):458–63. https://doi.org/10.1097/01.wco.0000245368.36576.0d.

Article  PubMed  CAS  Google Scholar 

Nobile-Orazio E, Barbieri S, Baldini L, Marmiroli P, Carpo M, Premoselli S, et al. Peripheral neuropathy in monoclonal gammopathy of undetermined significance: prevalence and immunopathogenetic studies. Acta Neurol Scand. 1992;85(6):383–90. https://doi.org/10.1111/j.1600-0404.1992.tb06033.x.

Article  PubMed  CAS  Google Scholar 

Nobile-Orazio E, Marmiroli P, Baldini L, Spagnol G, Barbieri S, Moggio M, et al. Peripheral neuropathy in macroglobulinemia: incidence and antigen-specificity of M proteins. Neurology. 1987;37(9):1506–14. https://doi.org/10.1212/wnl.37.9.1506.

Article  PubMed  CAS  Google Scholar 

D’Sa S, Kersten MJ, Castillo JJ, Dimopoulos M, Kastritis E, Laane E, et al. Investigation and management of IgM and Waldenstrom-associated peripheral neuropathies: recommendations from the IWWM-8 consensus panel. Br J Haematol. 2017;176(5):728–42. https://doi.org/10.1111/bjh.14492.

Article  PubMed  CAS  Google Scholar 

Garces-Sanchez M, Dyck PJ, Kyle RA, Zeldenrust S, Wu Y, Ladha SS, et al. Antibodies to myelin-associated glycoprotein (anti-Mag) in IgM amyloidosis may influence expression of neuropathy in rare patients. Muscle Nerve. 2008;37(4):490–5. https://doi.org/10.1002/mus.20955.

Article  PubMed  CAS  Google Scholar 

Terrier B, Jaccard A, Harousseau JL, Delarue R, Tournilhac O, Hunault-Berger M, et al. The clinical spectrum of IgM-related amyloidosis: a French nationwide retrospective study of 72 patients. Medicine (Baltimore). 2008;87(2):99–109. https://doi.org/10.1097/MD.0b13e31816c43b6.

Article  PubMed  CAS  Google Scholar 

Campagnolo M, Ruiz M, Falzone YM, Ermani M, Bianco M, Martinelli D, et al. Limitations in daily activities and general perception of quality of life: Long term follow-up in patients with anti-myelin-glycoprotein antibody polyneuropathy. J Peripher Nerv Syst. 2019;24(3):276–82. https://doi.org/10.1111/jns.12342.

Article  PubMed  CAS  Google Scholar 

Katz JS, Saperstein DS, Gronseth G, Amato AA, Barohn RJ. Distal acquired demyelinating symmetric neuropathy. Neurology. 2000;54(3):615–20. https://doi.org/10.1212/wnl.54.3.615.

Article  PubMed  CAS  Google Scholar 

Latov N. Pathogenesis and therapy of neuropathies associated with monoclonal gammopathies. Ann Neurol. 1995;37(Suppl 1):S32–42. https://doi.org/10.1002/ana.410370705.

Article  PubMed  Google Scholar 

Buske C, Castillo JJ, Abeykoon JP, Advani R, Arulogun SO, Branagan AR, et al. Report of consensus panel 1 from the 11(th) International Workshop on Waldenstrom’s Macroglobulinemia on management of symptomatic, treatment-naive patients. Semin Hematol. 2023;60(2):73–9. https://doi.org/10.1053/j.seminhematol.2023.03.005.

Article  PubMed  Google Scholar 

Dalakas MC, Rakocevic G, Salajegheh M, Dambrosia JM, Hahn AF, Raju R, et al. Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy. Ann Neurol. 2009;65(3):286–93. https://doi.org/10.1002/ana.21577.

Article  PubMed  CAS  Google Scholar 

Sala E, Robert-Varvat F, Paul S, Camdessanche JP, Antoine JC. Acute neurological worsening after Rituximab treatment in patients with anti-MAG neuropathy. J Neurol Sci. 2014;345(1–2):224–7. https://doi.org/10.1016/j.jns.2014.07.055.

Article  PubMed  CAS  Google Scholar 

Gironi M, Saresella M, Ceresa L, Calvo M, Ferrante P, Merli F, et al. Clinical and immunological worsening in a patient affected with Waldenstrom macroglobulinemia and anti-mag neuropathy after treatment with rituximab. Haematologica. 2006;91(6 Suppl):ECR17.

PubMed  Google Scholar 

Iancu Ferfoglia R, Guimaraes-Costa R, Viala K, Musset L, Neil J, Marin B, et al. Long-term efficacy of rituximab in IgM anti-myelin-associated glycoprotein neuropathy: RIMAG follow-up study. J Peripher Nerv Syst. 2016;21(1):10–4. https://doi.org/10.1111/jns.12156.

Article  PubMed  CAS  Google Scholar 

Leger JM, Viala K, Nicolas G, Creange A, Vallat JM, Pouget J, et al. Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein neuropathy. Neurology. 2013;80(24):2217–25. https://doi.org/10.1212/WNL.0b013e318296e92b.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Chaar D, Kakara M, Sriwastava S, Moshirzadeh S, Halon M, Lisak R. Characteristics of patients with anti-MAG associated neuropathy who respond to rituximab. Neurology. 2020;94. https://doi.org/10.1212/WNL.94.15_supplement.5242.

Hospital MA, Viala K, Dragomir S, Levy V, Cohen-Aubart F, Neil J, et al. Immunotherapy-based regimen in anti-MAG neuropathy: results in 45 patients. Haematologica. 2013;98(12):e155–7. https://doi.org/10.3324/haematol.2013.087213.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Castellani F, Visentin A, Campagnolo M, Salvalaggio A, Cacciavillani M, Candiotto C, et al. The Bruton tyrosine kinase inhibitor ibrutinib improves anti-MAG antibody polyneuropathy. Neurol Neuroimmunol Neuroinflamm. 2020;7(4):e720. https://doi.org/10.1212/NXI.0000000000000720.

Sarosiek S, Branagan AR, Doughty C, Flynn CA, Little M, Stockman K, et al. Prospective study of acalabrutinib with rituximab in patients with symptomatic anti-MAG mediated IgM peripheral neuropathy. Blood. 2023;142:213. https://doi.org/10.1182/blood-2023-185113.

Article  Google Scholar 

Stork AC, Jacobs BC, Tio-Gillen AP, Eurelings M, Jansen MD, van den Berg LH, et al. Prevalence, specificity and functionality of anti-ganglioside antibodies in neuropathy associated with IgM monoclonal gammopathy. J Neuroimmunol. 2014;268(1–2):89–94. https://doi.org/10.1016/j.jneuroim.2014.01.012.

Article  PubMed  CAS  Google Scholar 

Mata S, Borsini W, Ambrosini S, Toscani L, Barilaro A, Piacentini S, et al. IgM monoclonal gammopathy-associated neuropathies with different IgM specificity. Eur J Neurol. 2011;18(8):1067–73. https://doi.org/10.1111/j.1468-1331.2010.03345.x.

Article  PubMed  CAS  Google Scholar 

Rojas-Garcia R, Gallardo E, de Andres I, de Luna N, Juarez C, Sanchez P, et al. Chronic neuropathy with IgM anti-ganglioside antibodies: lack of long term response to rituximab. Neurology. 2003;61(12):1814–6. https://doi.org/10.1212/01.wnl.0000098996.02934.86.

Article  PubMed  CAS